T. Rowe Price Associates
BOLD

T. Rowe Price Associates’s Audentes Therapeutics, Inc BOLD Stock Holding History

T. Rowe Price Associates’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-394,539
Closed -$11.1M – 2571
2019
Q3 		$11.1M Sell
394,539
-232,342
-37% -$7.93M ﹤0.01% 1273
2019
Q2 		$23.7M Sell
626,881
-163,987
-21% -$6.3M ﹤0.01% 1133
2019
Q1 		$30.9M Sell
790,868
-100,313
-11% -$2.88M ﹤0.01% 1036
2018
Q4 		$19M Sell
891,181
-1,423,423
-61% -$36.7M ﹤0.01% 1162
2018
Q3 		$91.6M Sell
2,314,604
-21,700
-0.9% -$809K 0.01% 698
2018
Q2 		$89.3M Buy
2,336,304
+526,216
+29% +$19.5M 0.01% 696
2018
Q1 		$54.4M Buy
1,810,088
+264,711
+17% +$8.96M 0.01% 837
2017
Q4 		$48.3M Buy
1,545,377
+967,035
+167% +$26.6M 0.01% 883
2017
Q3 		$16.2M Sell
578,342
-23,600
-4% -$512K ﹤0.01% 1247
2017
Q2 		$11.5M Buy
601,942
+41,545
+7% +$664K ﹤0.01% 1296
2017
Q1 		$9.55M Sell
560,397
-18,200
-3% -$294K ﹤0.01% 1339
2016
Q4 		$10.3M Sell
578,597
-1,084
-0.2% -$18.7K ﹤0.01% 1312
2016
Q3 		$10M Buy
+579,681
New +$8.8M ﹤0.01% 1319

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates's BOLD Position: Q4 2019 in Review

T. Rowe Price Associates sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 394,539 shares — an estimated $11.1M sold.

T. Rowe Price Associates first reported a position in BOLD in Q3 2016 and held it in 13 quarters. The position peaked at $91.6M in Q3 2018. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • T. Rowe Price Associates reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • T. Rowe Price Associates sold 394,539 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $11.1M.
  • T. Rowe Price Associates first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 13 quarters.
  • T. Rowe Price Associates's Audentes Therapeutics, Inc position peaked at $91.6M in Q3 2018.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on T. Rowe Price Associates's 13F filing for Q4 2019, filed 14 Feb 2020.